Comment
Author: Admin | 2025-04-28
A long-acting injectable antipsychotic gaining popularity for treating schizophrenia. The drug is supposed to get off-patent by October 2024. Abilify Maintaina has aripiprazole in an extended release injectable suspension, dosed monthly for maintenance treatment of schizophrenia in adults. After its launch in 2013, Abilify Maintaina became a key choice for patients and doctors managing schizophrenia. According to experts, Abilify Maintena is poised to continue dominating this growing antipsychotic market.XARELTO: One of the top-selling drugs in the anticoagulant drug market, Xarelto, developed by Janssen Pharms is set to lose its patent in August 2024. Xarelto (rivaroxaban) is an oral direct factor Xa inhibitor that is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The drug is also prescribed for preventing deep vein thrombosis which may lead to pulmonary embolism following knee or hip replacement surgery.FARXIGA: Anti-diabetic drugs continue to be a major market. AstraZeneca’s Farxiga is one of the top drugs in this class. Farxiga (dapagliflozin) is an oral SGLT2 inhibitor used for improving glycemic control in adults with type 2 diabetes, both as monotherapy and as an add-on treatment. Since its launch, Farxiga has become a blockbuster diabetes drug for AstraZeneca, generating annual sales of around $4.3 billion, though it does come with side effects like urinary tract infections.Ozempic: Developed by Novo Nordisk, Ozempic (semaglutide) is an injectable GLP-1 analogue used for improving glycemic control in type 2 diabetes patients. Since its approval in 2017, Ozempic has rapidly become a blockbuster diabetes
Add Comment